Is VEGF Trap-Eye Effective in Treating Macular Edema?

December 21, 2010

On Monday, Regeneron Pharmaceuticals Inc. and Bayer HealthCare AG said Monday announced that their VEGF Trap-Eye drug met key treatment goals in a late-stage study on macular edema patients. The study focused on patients with macular edema because of central retinal vein occlusion.

Specifically, 56.1% of patients in the study receiving monthly injections reported improvement in vision (as compared to 12% in the control group).

Read the full story here on Bloomberg.




Jump down to form below to submit your own comments

Trackback URL

Have insights to contribute? Please submit your comment below